case_images: PMC6615020_01
case_images: Thoracic computed tomography images illustrating the size reduction of the pulmonary lesions after 2 months of afatinib treatment (lower panels) as compared to baseline (top panels).
case_images: OTT-12-5305-g0001.jpg
case_images: PMC6615020_01_OTT-12-5305-g0001.jpg
case_images: F0001
case_images: After 2 months of afatinib treatment, the patient achieved partial response (PR) reflected by the reduction of pulmonary lesions according to RECIST (Figure 1).
case_images: Serum tumor biomarker levels reduced after 1 to 2 months of afatinib treatment. Serum levels of biomarkers including CEA and CY211 expressed in ng/mL, CA19-9, CA125, CA15-3 expressed in units/mL and NSE expressed in microg/mL. X-axis denotes time point, baseline, 1 or 2 months after afatinib treatment. Y-axis denotes serum levels of biomarker.. Abbreviations: CEA, carcinoembryonic antigen; NSE, neuron-specific enolase.
case_images: OTT-12-5305-g0002.jpg
case_images: PMC6615020_01_OTT-12-5305-g0002.jpg
case_images: F0002
case_images: On the other hand, neuron-specific enolase (NSE), a specific tumor marker for small cell lung cancer, remained constant (Figure 2).